Abstract
INTRODUCTION
The drug delivery market is changing drastically due to the introduction of new techniques and routes of delivery. R&D spending, along with increasing competition, new technologies, an international marketplace, and a changing customer base, is creating a new kind of market for drug delivery systems. This study looks at almost all the systems affected by these factors.
This is a very complex market, where many technologies are combined to produce a better delivery system, thus creating niche markets with very specialized applications. The use of liposomes, polymers, etc. in the sustained release oral/injectable drug delivery market is a good example.
Pegylation, nanoparticles, polymers and liposomes are significant new markets. These technologies combined together could be a multibillion dollar global market in the next few years.
Acquisition strategies and collaborations by companies are also covered in this report, e.g., the acquisition of Guilford Pharmaceuticals by MGI Pharma, which added Gliadel Wafer (polifeprosan 20 with carmustine implant) to its portfolio. This study also discusses the strengths and weaknesses of the drug development market in light of new technologies, growing competition and changing customer needs.
SCOPE OF STUDY
This report contains:
- An overview of the major types of drug delivery systems used in the health industry
- Analysis of each technology with an in-depth look at manufacturers, the new products, sales estimates, market projections and market share information
- Discussion of the technological issues, including the latest trends and developments
- Forecasts of the U.S. market and its various sectors, with 5-year projections to 2011
- Profiles of the major players within the industry and a detailed patent analysis.
METHODOLOGY
A comprehensive literature and patent search was conducted. The literature included technical newsletters and journals, as well as many other sources. The data were collected through interviews with leading pharmaceutical and biotech sources. Projections were based on estimates of the current number of end users, potential end users, likely unit prices, rates of consumption and othermarket trends.
Table of Contents
- INTRODUCTION
- STUDY OBJECTIVES
- REASONS FOR DOING THIS STUDY
- CONTRIBUTIONS OF THE STUDY AND FOR WHOM
- SCOPE OF THE STUDY
- METHODOLOGY
- INFORMATION SOURCES
- ABOUT THE AUTHOR
- RELATED BCC REPORTS
- DISCLAIMER
- EXECUTIVE SUMMARY
- Summary Table:
- U.S. MARKET FORECAST OF ADVANCED DRUG DELIVERY SYSTEMS THROUGH 2011 ($ BILLIONS)
- Summary Figure:
- U.S. MARKET FOR ADVANCED DRUG DELIVERY SYSTEMS 2004-2011 ($ BILLIONS)
- OVERVIEW
- DOSAGE FORMS
- DIFFERENT TYPES OF DOSAGE FORMS
- WHAT IS DRUG DELIVERY?
- ROUTES OF DRUG DELIVERY
- TECHNOLOGIES FOR DRUG DELIVERY
- Sustained Release
- Delayed Release
- Prodrugs
- Implants and Pumps for Drug Delivery
- Targeted Delivery Systems
- Receptor-Mediated Targeted Drug Delivery
- CLASSIFICATION OF DRUG DELIVERY SYSTEMS
- DOSAGE FORMS
- REGULATORY ISSUES
- THE ROLE OF REGULATORY AUTHORITIES IN DRUG DELIVERY
- Table 1 REGULATORY ACTION TAKEN FOR SAFE DRUG USAGE FOR DRUG DELIVERY
SYSTEMS
- USE OF EXCIPIENTS
- INDUSTRY STRUCTURE
- DRUG DELIVERY SYSTEMS PRODUCT SEGMENTS
- SUSTAINED RELEASE ORAL DOSAGE FORMS
- DIFFUSIONAL AND DISSOLUTION SYSTEMS
- MARKET LEADERS
- Table 2 MAJOR SUPPLIERS AND MANUFACTURERS OF SUSTAINED RELEASE ORAL DOSAGE FORMS, 2005
- Table 3 U.S. MARKET FOR SUSTAINED RELEASE ORAL DOSAGE FORMS BY MANUFACTURER, 2005 (%)
- Figure 1 U.S. MARKET SHARE FOR SUSTAINED RELEASE ORAL DOSAGE FORMS BY
MANUFACTURER, 2005 (%)
- SUSTAINED RELEASE INJECTABLE DOSAGE FORMS
- MARKET LEADERS
- SUSTAINED RELEASE INJECTABLE DOSAGE FORMS
- Table 4 MAJOR SUPPLIERS AND MANUFACTURERS OF SUSTAINED RELEASE INJECTABLE DOSAGE FORMS, 2005
- Table 5 U.S. SUSTAINED RELEASE INJECTABLE DOSAGE FORM MARKET BY MANUFACTURER, 2005 (%)
- Figure 2 U.S. SUSTAINED RELEASE INJECTABLE DOSAGE FORMS MARKET BY
MANUFACTURER, 2005 (%)
- SUSTAINED RELEASE TOPICAL DOSAGE FORMS
- MARKET LEADERS
- SUSTAINED RELEASE TOPICAL DOSAGE FORMS
- Table 6 MAJOR SUPPLIERS AND MANUFACTURERS OF SUSTAINED RELEASE TOPICAL DOSAGE FORMS, 2005
- Table 7 U.S. MARKET FOR SUSTAINED RELEASE TOPICAL DOSAGE FORMS BY MANUFACTURER, 2005 (%)
- Figure 3 U.S.MARKET FOR SUSTAINED RELEASE TOPICAL DOSAGE FORMS BY
MANUFACTURER, 2005 (%)
- IMPLANTS AND IUDS
- MARKET LEADERS
- IMPLANTS AND IUDS
- Table 8 MAJOR SUPPLIERS AND MANUFACTURERS OF IMPLANTS AND IUDS
- Table 9 U.S. MARKET FOR IMPLANTS AND IUDS BY MANUFACTURER, 2005 (%)
- Figure 4 U.S. MARKET FOR IMPLANTS AND IUDS BY MANUFACTURER, 2005 (%)
- TRANSDERMAL DRUG DELIVERY SYSTEM (TDDS)
- MARKET LEADERS
- TRANSDERMAL DRUG DELIVERY SYSTEM (TDDS)
- Table 10 MAJOR SUPPLIERS AND MANUFACTURERS OF TRANSDERMAL DRUG DELIVERY SYSTEMS, 2005
- Table 11 U.S. MARKET FOR PATCH-DELIVERED DRUGS USED IN TRANSDERMAL DRUG DELIVERY SYSTEMS BY TYPE, 2005 (%)
- Figure 5 U.S MARKET FOR PATCH DELIVERED DRUGS USED IN TRANSDERMAL DRUG DELIVERY SYSTEMS BY TYPE, 2005 (%)
- Table 12 U.S. MARKET FOR SUPPLIERS AND MANUFACTURERS OF TDDS, 2005 (%)
- Figure 6 U.S. MARKET FOR TDDS BY MANUFACTURER, 2005 (%)
- TARGETED DELIVERY SYSTEMS
- LIPOSOMES
- MARKET LEADERS
- TARGETED DELIVERY SYSTEMS
- Table 13 MAJOR SUPPLIERS AND MANUFACTURERS OF LIPOSOMES, 2005
- Table 14 U.S. LIPOSOME DRUG MARKET BY TYPE, 2005 (%)
- Figure 7 U.S LIPOSOME DRUG MARKET BY TYPE, 2005 (%)
- Table 15 U.S. LIPOSOME MARKET BY MANUFACTURER, 2005 (%)
- Figure 8 U.S. LIPOSOME MARKET BY MANUFACTURER, 2005 (%)
- NANOPARTICLES
- Table 16 MAJOR SUPPLIERS AND MANUFACTURERS OF NANOPARTICLES, 2005
- Table 17 U.S. NANOPARTICLE MARKET BY MANUFACTURER, 2005 (%)
- Figure 9 U.S. NANOPARTICLE MARKET BY MANUFACTURER, 2005 (%)
- POLYMERS
- MARKET LEADERS
- POLYMERS
- Table 18 MAJOR SUPPLIERS AND MANUFACTURERS OF POLYMERS, 2005
- MONOCLONAL ANTIBODIES
- MARKET LEADERS
- MONOCLONAL ANTIBODIES
- Table 19 MAJOR SUPPLIERS AND MANUFACTURERS OF MONOCLONAL ANTIBODIES, 2005
- Table 20 U.S. MARKET FOR MONOCLONAL ANTIBODIES BY MANUFACTURER, 2005 (%)
- Figure 10 U.S. MARKET FOR MONOCLONAL ANTIBODIES, BY MANUFACTURER, 2005
(%)
- PEGNOLOGY
- MARKET LEADERS
- PEGNOLOGY
- Table 21 MAJOR SUPPLIERS AND MANUFACTURERS OF PEGNOLOGY, 2005
- Table 22 U.S. MARKET FOR PEGNOLOGY BY MANUFACTURER, 2005 (%)
- Figure 11 U.S. MARKET FOR PEGNOLOGY BY MANUFACTURER, 2005 (%)
- TRANSMUCOSAL DRUG DELIVERY SYSTEMS
- INHALATION SYSTEMS
- MARKET LEADERS
- Table 23 MAJOR SUPPLIERS AND MANUFACTURERS OF INHALATION SYSTEMS, 2005
- Table 24 U.S. MARKET FOR INHALATION SYSTEMS BY MANUFACTURER, 2005 (%)
- Figure 12 U.S. MARKET FOR INHALATION SYSTEMS BY MANUFACTURER, 2005 (%)
- BUCCAL DELIVERY
- MARKET LEADERS
- BUCCAL DELIVERY
- Table 25 MAJOR SUPPLIERS AND MANUFACTURERS OF BUCCAL DELIVERY SYSTEMS, 2005
- Table 26 U.S. MARKET FOR BUCCAL DELIVERY SYSTEMS BY MANUFACTURER, 2005 (%)
- Figure 13 U.S. MARKET SHARE FORBUCCAL DELIVERY SYSTEMS BY MANUFACTURER,
2005 (%)
- RECTAL DELIVERY
- MARKET LEADERS
- RECTAL DELIVERY
- Table 27 MAJOR SUPPLIERS AND MANUFACTURERS OF RECTAL DELIVERY SYSTEMS, 2005
- Table 28 U.S. MARKET FOR RECTAL DELIVERY SYSTEMS BY MANUFACTURER, 2005 (%)
- Figure 14 U.S. MARKET FOR RECTAL DELIVERY SYSTEMS BY MANUFACTURER, 2005
(%)
- VAGINAL DELIVERY
- MARKET LEADERS
- VAGINAL DELIVERY
- Table 29 MAJOR SUPPLIERS AND MANUFACTURERS OF VAGINAL DELIVERY SYSTEMS, 2005
- Table 30 U.S. MARKET FOR VAGINAL DELIVERY SYSTEMS BY MANUFACTURER, 2005 (%)
- Figure 15 U.S. MARKET FORVAGINAL DELIVERY SYSTEMS BY MANUFACTURER, 2005
(%)
- OCULAR DELIVERY
- MARKET LEADERS
- Table 31 MAJOR SUPPLIERS AND MANUFACTURERS OF OCULAR DELIVERY SYSTEMS, 2005
- Table 32 U.S. MARKET FOR OCULAR DELIVERY SYSTEMS BY MANUFACTURER, 2005 (%)
- Figure 16 U.S. MARKET FOROCULAR DELIVERY SYSTEMS BY MANUFACTURER, 2005
(%)
- OTHERS
- VACCINES
- POLYCLONAL ANTIBODIES
- FACTORS GOVERNING DEMAND AND USE
- IMPROVING EFFICACY
- ENVIRONMENTAL CONCERNS
- BENEFITS OF DRUG DELIVERY
- Compliance
- Efficacy and Safety
- Benefits to Pharmaceutical and Biotech Companies
- Rescuing Research and Development Dropouts
- Reducing Side Effects
- OTHERS
- TECHNOLOGY
- NEW PRODUCT DEVELOPMENTS
- Table 33 DEVELOPMENTS IN SUSTAINED RELEASE ORAL DOSAGE FORMS
- Table 34 DEVELOPMENTS IN SUSTAINED RELEASE INJECTABLE DOSAGE FORMS
- Table 35 DEVELOPMENTS IN SUSTAINED RELEASE TOPICAL DOSAGE FORMS
- Table 36 DEVELOPMENTS IN TRANSDERMAL DRUG DELIVERY SYSTEMS
- Table 37 DEVELOPMENTS IN LIPOSOMES
- Table 38 DEVELOPMENTS IN NANOPARTICLES
- Table 39 DEVELOPMENTS IN POLYMER
- Table 40 DEVELOPMENTS IN MONOCLONAL ANTIBODIES
- Table 41 DEVELOPMENTS IN PEGNOLOGY
- Table 42 DEVELOPMENTS IN INHALATION SYSTEMS
- Table 43 DEVELOPMENTS IN BUCCAL DELIVERY
- Table 44 DEVELOPMENTS IN VAGINAL DELIVERY
- Table 45 DEVELOPMENTS IN OCULAR DELIVERY
- Table 46 DEVELOPMENTS IN VACCINE DELIVERY
- MARKETS FOR DRUG DELIVERY TECHNOLOGY
- SUSTAINED RELEASE ORAL DOSAGE FORM
- PELLETIZED PULSATILE DELIVERY SYSTEM
- SINGLE COMPOSITION OSMOTIC TABLET SYSTEM
- SOLUBILITY MODULATING HYDROGEL SYSTEM
- DELAYED PULSATILE HYDOGEL SYSTEM (DPHS)
- STABILIZED PELLET DELIVERY SYSTEM
- GRANULATED MODULATING HYDROGEL SYSTEM
- PELLETIZED TABLET SYSTEM
- POROUS TABLET SYSTEM
- STABILIZED TABLET DELIVERY SYSTEM
- DIRECTLY COMPRESSIBLE HYDROGEL SYSTEM
- MODULATING MATRIX SYSTEM
- PULSATILE ENTERIC COATING SYSTEM
- PELLETIZED DELIVERY SYSTEM
- Table 47 U.S. MARKET FORECAST FOR SUSTAINED RELEASE ORAL DOSAGE FORMS, THROUGH 2011 ($ BILLIONS)
- Figure 17 U.S. MARKET FOR SUSTAINED RELEASE ORAL DOSAGE FORMS, 2004-2011
($ BILLIONS)
- SUSTAINED RELEASE INJECTABLE DOSAGE FORM
- Table 48 U.S. MARKET FORECAST FOR SUSTAINED RELEASE INJECTABLE DOSAGE FORMS, THROUGH 2011 ($ BILLIONS)
- Figure 18 U.S. MARKET FOR SUSTAINED RELEASE INJECTABLE DOSAGE FORMS ($
BILLIONS)
- SUSTAINED RELEASE TOPICAL DOSAGE FORMS
- Table 49 U.S. MARKET FORECAST FOR SUSTAINED RELEASE TOPICAL DOSAGE FORMS, THROUGH 2011 ($ MILLIONS)
- Figure 19 U.S. MARKET FOR SUSTAINED RELEASE TOPICAL DOSAGE FORMS,
2004-2011 ($ MILLIONS)
- IMPLANTS AND INTRAUTRINE DEVICES (IUDS)
- Table 50 U.S. MARKET FORECAST FOR IMPLANTS AND IUDS, THROUGH 2011 ($ BILLIONS)
- Figure 20 U.S. MARKET FOR IMPLANTS AND IUDS, 2004-2011 ($ BILLIONS)
- TRANSDERMAL DRUG DELIVERY SYSTEMS
- Table 51 U.S. MARKET FORECAST FOR TDDS, THROUGH 2011 ($ BILLIONS)
- Figure 21 U.S. MARKET FOR TDDS, 2004-2011 ($ BILLIONS)
- TARGETED DELIVERY SYSTEMS
- Table 52 U.S. MARKET FORECAST FOR TARGETED DELIVERY SYSTEMS, THROUGH 2011 ($ MILLIONS)
- Figure 22 U.S. MARKET FOR TARGETED DELIVERY SYSTEMS 2004-2011 ($
MILLIONS)
- TRANSMUCOSAL DELIVERY SYSTEMS
- Table 53 U.S. MARKET FORECAST FOR TRANSMUCOSAL DELIVERY SYSTEMS, THROUGH 2011 ($ MILLIONS)
- Figure 23 U.S. MARKET FOR TRANSMUCOSAL DELIVERY SYSTEMS, 2004-2011 ($ MILLIONS)
- SUSTAINED RELEASE ORAL DOSAGE FORM
- PATENTS
- PATENTS BY YEAR
- Table 54 ANNUAL NUMBER OF PATENTS, 2003-2006
- Figure 24 ANNUAL NUMBER OF PATENTS, 2003-2006 (UNITS)
- Figure 25 ANNUAL NUMBER OF PATENTS, 2003-2005 (%)
- PATENTS BY TECHNOLOGY
- Table 55 DRUG DELIVERY PATENTS BY CATEGORY, 2003-2006
- Figure 26 NUMBER OF DRUG DELIVERY PATENTS BY CATEGORY, 2003-2006 (UNITS)
- Figure 27 DRUG DELIVERY PATENTS BY CATEGORY, 2003-2006 (%)
- SIGNIFICANT PATENTS OF 2006
- Table 56 SIGNIFICANT PATENTS FOR DRUG DELIVERY, 2006
- PATENTS BY COMPANY
- Table 57 U.S. PATENTS BY COMPANY, 2003-2006 (UNITS)
- PATENTS BY COUNTRY
- Table 58 NUMBER OF DRUG DELIVERY PATENTS BY COUNTRY, 2003-2006
- Table 59 TRENDS OF DRUG DELIVERY PATENTS ISSUED BY COUNTRY, 2003-2006
(UNITS/%)
- PATENTS BY ASSIGNEE
- Table 60 SHARES OF U.S. PATENTS BY ASSIGNEE, 2003-2006 (UNIT/%)
- Figure 28 SHARES OF U.S. PATENTS BY ASSIGNEE, 2003-2006 (UNITS)
- Figure 29 SHARES OF U.S. PATENTS BY ASSIGNEE, 2003-2006 (%)
- MARKETS BY PRODUCT
- MARKETS BY PRODUCT
- Table 61 U.S. MARKET FOR DRUG DELIVERY SYSTEMS BY PRODUCT SEGMENT, 2005
(%)
- CARDIOVASCULAR
- Table 62 U.S. MARKET FORECAST FOR CARDIOVASCULAR DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
- Figure 30 U.S. MARKET FOR CARDIOVASCULAR DRUG DELIVERY SYSTEMS,
2004-2011 ($ BILLIONS)
- ONCOLOGY
- Table 63 U.S. MARKET FORECAST FOR ONCOLOGY DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
- Figure 31 U.S. MARKET FOR ONCOLOGY DRUG DELIVERY SYSTEM, 2004-2011 ($
BILLIONS)
- UROLOGY
- Table 64 U.S. MARKET FORECAST FOR UROLOGY DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
- Figure 32 U.S. MARKET FOR UROLOGY DRUG DELIVERY SYSTEMS, 2004-2011 ($
BILLIONS)
- DIABETES
- Table 65 U.S. MARKET FORECAST FOR DIABETES DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
- Figure 33 U.S. MARKT FOR DIABETES DRUG DELIVERY SYSTEMS, 2004-2011 ($
BILLIONS)
- RESPIRATORY
- Table 66 U.S. MARKET FORECAST FOR RESPIRATORY DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
- Figure 34 U.S. MARKET FOR RESPIRATORY DRUG DELIVERY SYSTEMS, 2004-2011
($ BILLIONS)
- ANTI-INFLAMMATORY AND ALLERGY DRUG DELIVERY
- Table 67 U.S. MARKET FORECAST FOR ANTI-INFLAMMATORY AND ALLERGY DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
- Figure 35 U.S. MARKET FOR ANTI-INFLAMMATORY AND ALLERGY DRUG DELIVERY
SYSTEMS, 2004-2011 ($ BILLIONS)
- ANTIBIOTICS
- Table 68 U.S. MARKET FORECAST FOR ANTIBIOTIC DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
- Figure 36 U.S. MARKET FOR ANTIBIOTIC DRUG DELIVERY SYSTEMS, 2004-2011 ($
BILLIONS)
- ANTI-ANXIETY AND ANTI-DEPRESSANTS
- Table 69 U.S. MARKET FORECAST FOR ANTIANXIETY AND ANTIDEPRESSANT DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
- Figure 37 U.S. MARKET FOR ANTI-ANXIETY AND ANTI-DEPRESSANT DRUG DELIVERY
SYSTEMS, 2004-2011 ($ BILLIONS)
- HORMONES AND GYNECOLOGY
- Table 70 U.S. MARKET FOR HORMONE AND GYNECOLOGY DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
- Figure 38 U.S. MARKET FOR HORMONES AND GYNECOLOGY DRUG DELIVERY SYSTEMS,
2004-2011 ($ BILLIONS)
- OPHTHALMIC
- Table 71 U.S. MARKET FORECAST FOR OPHTHALMIC DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
- Figure 39 U.S. MARKET FOR OPHTHALMIC DRUG DELIVERY SYSTEMS, 2004-2011 ($
BILLIONS)
- IMMUNE DISEASES
- Table 72 U.S. MARKET FORECAST FOR IMMUNE DISEASEDRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
- Figure 40 U.S. MARKET FOR IMMUNE DISEASEDRUG DELIVERY SYSTEMS, 2004-2011
($ BILLION)
- OTHERS
- Table 73 U.S. MARKET FORECAST FOR OTHERS CATEGORY IN DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
- Figure 41 U.S. MARKET FOR OTHERS CATEGORY IN DRUG DELIVERY SYSTEMS, 2004-2011 ($ BILLIONS)
- Table 74 U.S. MARKET SHARES OF DEVELOPMENTS IN DRUG DELIVERY SYSTEMS, 2005 (%)
- INTERNATIONAL ASPECTS
- ASIA
- EUROPE
- REGIONAL COMPARISONS
- Table 75 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS, 2005 (%)
- Figure 42 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS, 2005 (%)
- SUSTAINED RELEASE DOSAGE FORM (ORAL, INJECTABLE, TOPICAL) DRUG DELIVERY SYSTEMS
- Table 76 GLOBAL MARKET FORECAST FOR SUSTAINED RELEASE DOSAGE (ORAL, INJECTABLE, TOPICAL) DRUG DELIVERY SYSTEMS BY REGION, THROUGH 2011 ($ BILLIONS)
- Figure 43 GLOBAL MARKET FOR SUSTAINED RELEASE DOSAGE (ORAL, INJECTABLE,
TOPICAL) DRUG DELIVERY SYSTEMS, 2004-2011 ($ BILLIONS)
- IMPLANTS AND IUDS DRUG DELIVERY SYSTEMS
- Table 77 GLOBAL MARKET FORECAST FOR IMPLANT AND IUD DRUG DELIVERY SYSTEMS BY REGION, THROUGH 2011 ($ BILLIONS)
- Figure 44 GLOBAL MARKET FOR IMPLANTS AND IUD DRUG DELIVERY SYSTEMS,
2004-2011 ($ BILLIONS)
- TRANSDERMAL DRUG DELIVERY SYSTEMS
- Table 78 GLOBAL MARKET FORECAST FOR TRANSDERMAL DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
- Figure 45 GLOBAL MARKET FORECAST FOR TRANSDERMAL DRUG DELIVERY SYSTEMS,
THROUGH 2011 ($ BILLIONS)
- TARGETED DRUG DELIVERY SYSTEM, THROUGH 2011
- Table 79 GLOBAL MARKET FORECAST FOR TARGETED DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
- Figure 46 GLOBAL MARKET FOR TARGETED DRUG DELIVERY SYSTEMS, 2004-2011 ($
BILLIONS)
- GLOBAL MARKET FOR Transmucosal Drug Delivery SYSTEMS THROUGH 2011
- Table 80 GLOBAL MARKET FORECAST FOR TRANSMUCOSAL DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
- Figure 47 GLOBAL MARKET FOR TRANSMUCOSAL DRUG DELIVERY SYSTEMS 2004-2011 ($ BILLION)
- COMPANY PROFILES
- ABBOTT LABORATORIES
- APP-ABRAXIS PHARMACEUTICAL PRODUCTS
- ASTRAZENECA PHARMACEUTICALS
- ALKERMES
- ADVANCED POLYMER PHARMA INC. (A.P. PHARMA)
- AVENTIS PHARMACEUTICAL INC.
- AKORN INC.
- ANTIGENICS INC.
- ARADIGM CORP.
- ANDRX CORP. (ACQUIRED BY WATSON IN 2006)
- BAYER CORP.
- BIOVAIL CORP.
- BERLEX LABORATORIES, INC.
- BIOSANTE PHARMACEUTICALS, INC.
- CARDINAL HEALTH, INC.
- ELAN
- ENZON, INC.
- EURAND
- GENENTECH INC.
- GILEAD
- JOHNSON & JOHNSON
- KV PHARMACEUTICAL CO.
- 3M PHARMACEUTICALS
- MEDIMMUNE, INC.
- MGI PHARMA
- MYLAN LABORATORIES INC.
- NEKTAR THERAPEUTICS
- NOVEN PHARMACEUTICALS, INC.
- NOVAVAX, INC.
- PFIZER INC.
- PROTEIN DESIGN LABS
- QLT USA INC.
- SONTRA MEDICAL CORP.
- SCHERING-PLOUGH CORP.
- SOUTHERN RESEARCH INSTITUTE
- SKYEPHARMA
- WATSON PHARMACEUTICALS, INC.
- WYETH
- LIST OF TABLES
- Summary Table:
- U.S. MARKET FORECAST OF ADVANCED DRUG DELIVERY SYSTEMS THROUGH 2011 ($ BILLIONS)
- Table 1 REGULATORY ACTION TAKEN FOR SAFE DRUG USAGE FOR DRUG DELIVERY SYSTEMS
- Table 2 MAJOR SUPPLIERS AND MANUFACTURERS OF SUSTAINED RELEASE ORAL DOSAGE FORMS, 2005
- Table 3 U.S. MARKET FOR SUSTAINED RELEASE ORAL DOSAGE FORMS BY MANUFACTURER, 2005 (%)
- Table 4 MAJOR SUPPLIERS AND MANUFACTURERS OF SUSTAINED RELEASE INJECTABLE DOSAGE FORMS, 2005
- Table 5 U.S. SUSTAINED RELEASE INJECTABLE DOSAGE FORM MARKET BY MANUFACTURER, 2005 (%)
- Table 6 MAJOR SUPPLIERS AND MANUFACTURERS OF SUSTAINED RELEASE TOPICAL DOSAGE FORMS, 2005
- Table 7 U.S. MARKET FOR SUSTAINED RELEASE TOPICAL DOSAGE FORMS BY MANUFACTURER, 2005 (%)
- Table 8 MAJOR SUPPLIERS AND MANUFACTURERS OF IMPLANTS AND IUDS
- Table 9 U.S. MARKET FOR IMPLANTS AND IUDS BY MANUFACTURER, 2005 (%)
- Table 10 MAJOR SUPPLIERS AND MANUFACTURERS OF TRANSDERMAL DRUG DELIVERY SYSTEMS, 2005
- Table 11 U.S. MARKET FOR PATCH-DELIVERED DRUGS USED IN TRANSDERMAL DRUG DELIVERY SYSTEMS BY TYPE, 2005 (%)
- Table 12 U.S. MARKET FOR SUPPLIERS AND MANUFACTURERS OF TDDS, 2005 (%)
- Table 13 MAJOR SUPPLIERS AND MANUFACTURERS OF LIPOSOMES, 2005
- Table 14 U.S. LIPOSOME DRUG MARKET BY TYPE, 2005 (%)
- Table 15 U.S. LIPOSOME MARKET BY MANUFACTURER, 2005 (%)
- Table 16 MAJOR SUPPLIERS AND MANUFACTURERS OF NANOPARTICLES, 2005
- Table 17 U.S. NANOPARTICLE MARKET BY MANUFACTURER, 2005 (%)
- Table 18 MAJOR SUPPLIERS AND MANUFACTURERS OF POLYMERS, 2005
- Table 19 MAJOR SUPPLIERS AND MANUFACTURERS OF MONOCLONAL ANTIBODIES, 2005
- Table 20 U.S. MARKET FOR MONOCLONAL ANTIBODIES BY MANUFACTURER, 2005 (%)
- Table 21 MAJOR SUPPLIERS AND MANUFACTURERS OF PEGNOLOGY, 2005
- Table 22 U.S. MARKET FOR PEGNOLOGY BY MANUFACTURER, 2005 (%)
- Table 23 MAJOR SUPPLIERS AND MANUFACTURERS OF INHALATION SYSTEMS, 2005
- Table 24 U.S. MARKET FOR INHALATION SYSTEMS BY MANUFACTURER, 2005 (%)
- Table 25 MAJOR SUPPLIERS AND MANUFACTURERS OF BUCCAL DELIVERY SYSTEMS, 2005
- Table 26 U.S. MARKET FOR BUCCAL DELIVERY SYSTEMS BY MANUFACTURER, 2005 (%)
- Table 27 MAJOR SUPPLIERS AND MANUFACTURERS OF RECTAL DELIVERY SYSTEMS, 2005
- Table 28 U.S. MARKET FOR RECTAL DELIVERY SYSTEMS BY MANUFACTURER, 2005 (%)
- Table 29 MAJOR SUPPLIERS AND MANUFACTURERS OF VAGINAL DELIVERY SYSTEMS, 2005
- Table 30 U.S. MARKET FOR VAGINAL DELIVERY SYSTEMS BY MANUFACTURER, 2005 (%)
- Table 31 MAJOR SUPPLIERS AND MANUFACTURERS OF OCULAR DELIVERY SYSTEMS, 2005
- Table 32 U.S. MARKET FOR OCULAR DELIVERY SYSTEMS BY MANUFACTURER, 2005 (%)
- Table 33 DEVELOPMENTS IN SUSTAINED RELEASE ORAL DOSAGE FORMS
- Table 34 DEVELOPMENTS IN SUSTAINED RELEASE INJECTABLE DOSAGE FORMS
- Table 35 DEVELOPMENTS IN SUSTAINED RELEASE TOPICAL DOSAGE FORMS
- Table 36 DEVELOPMENTS IN TRANSDERMAL DRUG DELIVERY SYSTEMS
- Table 37 DEVELOPMENTS IN LIPOSOMES
- Table 38 DEVELOPMENTS IN NANOPARTICLES
- Table 39 DEVELOPMENTS IN POLYMER
- Table 40 DEVELOPMENTS IN MONOCLONAL ANTIBODIES
- Table 41 DEVELOPMENTS IN PEGNOLOGY
- Table 42 DEVELOPMENTS IN INHALATION SYSTEMS
- Table 43 DEVELOPMENTS IN BUCCAL DELIVERY
- Table 44 DEVELOPMENTS IN VAGINAL DELIVERY
- Table 45 DEVELOPMENTS IN OCULAR DELIVERY
- Table 46 DEVELOPMENTS IN VACCINE DELIVERY
- Table 47 U.S. MARKET FORECAST FOR SUSTAINED RELEASE ORAL DOSAGE FORMS, THROUGH 2011 ($ BILLIONS)
- Table 48 U.S. MARKET FORECAST FOR SUSTAINED RELEASE INJECTABLE DOSAGE FORMS, THROUGH 2011 ($ BILLIONS)
- Table 49 U.S. MARKET FORECAST FOR SUSTAINED RELEASE TOPICAL DOSAGE FORMS, THROUGH 2011 ($ MILLIONS)
- Table 50 U.S. MARKET FORECAST FOR IMPLANTS AND IUDS, THROUGH 2011 ($ BILLIONS)
- Table 51 U.S. MARKET FORECAST FOR TDDS, THROUGH 2011 ($ BILLIONS)
- Table 52 U.S. MARKET FORECAST FOR TARGETED DELIVERY SYSTEMS, THROUGH 2011 ($ MILLIONS)
- Table 53 U.S. MARKET FORECAST FOR TRANSMUCOSAL DELIVERY SYSTEMS, THROUGH 2011 ($ MILLIONS)
- Table 54 ANNUAL NUMBER OF PATENTS, 2003-2006
- Table 55 DRUG DELIVERY PATENTS BY CATEGORY, 2003-2006
- Table 56 SIGNIFICANT PATENTS FOR DRUG DELIVERY, 2006
- Table 57 U.S. PATENTS BY COMPANY, 2003-2006 (UNITS)
- Table 58 NUMBER OF DRUG DELIVERY PATENTS BY COUNTRY, 2003-2006
- Table 59 TRENDS OF DRUG DELIVERY PATENTS ISSUED BY COUNTRY, 2003-2006 (UNITS/%)
- Table 60 SHARES OF U.S. PATENTS BY ASSIGNEE, 2003-2006 (UNIT/%)
- Table 61 U.S. MARKET FOR DRUG DELIVERY SYSTEMS BY PRODUCT SEGMENT, 2005 (%)
- Table 62 U.S. MARKET FORECAST FOR CARDIOVASCULAR DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
- Table 63 U.S. MARKET FORECAST FOR ONCOLOGY DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
- Table 64 U.S. MARKET FORECAST FOR UROLOGY DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
- Table 65 U.S. MARKET FORECAST FOR DIABETES DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
- Table 66 U.S. MARKET FORECAST FOR RESPIRATORY DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
- Table 67 U.S. MARKET FORECAST FOR ANTI-INFLAMMATORY AND ALLERGY DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
- Table 68 U.S. MARKET FORECAST FOR ANTIBIOTIC DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
- Table 69 U.S. MARKET FORECAST FOR ANTIANXIETY AND ANTIDEPRESSANT DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
- Table 70 U.S. MARKET FOR HORMONE AND GYNECOLOGY DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
- Table 71 U.S. MARKET FORECAST FOR OPHTHALMIC DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
- Table 72 U.S. MARKET FORECAST FOR IMMUNE DISEASEDRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
- Table 73 U.S. MARKET FORECAST FOR OTHERS CATEGORY IN DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
- Table 74 U.S. MARKET SHARES OF DEVELOPMENTS IN DRUG DELIVERY SYSTEMS, 2005 (%)
- Table 75 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS, 2005 (%)
- Table 76 GLOBAL MARKET FORECAST FOR SUSTAINED RELEASE DOSAGE (ORAL, INJECTABLE, TOPICAL) DRUG DELIVERY SYSTEMS BY REGION, THROUGH 2011 ($ BILLIONS)
- Table 77 GLOBAL MARKET FORECAST FOR IMPLANT AND IUD DRUG DELIVERY SYSTEMS BY REGION, THROUGH 2011 ($ BILLIONS)
- Table 78 GLOBAL MARKET FORECAST FOR TRANSDERMAL DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
- Table 79 GLOBAL MARKET FORECAST FOR TARGETED DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
- Table 80 GLOBAL MARKET FORECAST FOR TRANSMUCOSAL DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
- LIST OF FIGURES
- Summary Figure:
- U.S. MARKET FOR ADVANCED DRUG DELIVERY SYSTEMS 2004-2011 ($ BILLIONS)
- Figure 1 U.S. MARKET SHARE FOR SUSTAINED RELEASE ORAL DOSAGE FORMS BY MANUFACTURER, 2005 (%)
- Figure 2 U.S. SUSTAINED RELEASE INJECTABLE DOSAGE FORMS MARKET BY MANUFACTURER, 2005 (%)
- Figure 3 U.S.MARKET FOR SUSTAINED RELEASE TOPICAL DOSAGE FORMS BY MANUFACTURER, 2005 (%)
- Figure 4 U.S. MARKET FOR IMPLANTS AND IUDS BY MANUFACTURER, 2005 (%)
- Figure 5 U.S MARKET FOR PATCH DELIVERED DRUGS USED IN TRANSDERMAL DRUG DELIVERY SYSTEMS BY TYPE, 2005 (%)
- Figure 6 U.S. MARKET FOR TDDS BY MANUFACTURER, 2005 (%)
- Figure 7 U.S LIPOSOME DRUG MARKET BY TYPE, 2005 (%)
- Figure 8 U.S. LIPOSOME MARKET BY MANUFACTURER, 2005 (%)
- Figure 9 U.S. NANOPARTICLE MARKET BY MANUFACTURER, 2005 (%)
- Figure 10 U.S. MARKET FOR MONOCLONAL ANTIBODIES, BY MANUFACTURER, 2005 (%)
- Figure 11 U.S. MARKET FOR PEGNOLOGY BY MANUFACTURER, 2005 (%)
- Figure 12 U.S. MARKET FOR INHALATION SYSTEMS BY MANUFACTURER, 2005 (%)
- Figure 13 U.S. MARKET SHARE FORBUCCAL DELIVERY SYSTEMS BY MANUFACTURER, 2005 (%)
- Figure 14 U.S. MARKET FOR RECTAL DELIVERY SYSTEMS BY MANUFACTURER, 2005 (%)
- Figure 15 U.S. MARKET FORVAGINAL DELIVERY SYSTEMS BY MANUFACTURER, 2005 (%)
- Figure 16 U.S. MARKET FOROCULAR DELIVERY SYSTEMS BY MANUFACTURER, 2005 (%)
- Figure 17 U.S. MARKET FOR SUSTAINED RELEASE ORAL DOSAGE FORMS, 2004-2011 ($ BILLIONS)
- Figure 18 U.S. MARKET FOR SUSTAINED RELEASE INJECTABLE DOSAGE FORMS ($ BILLIONS)
- Figure 19 U.S. MARKET FOR SUSTAINED RELEASE TOPICAL DOSAGE FORMS, 2004-2011 ($ MILLIONS)
- Figure 20 U.S. MARKET FOR IMPLANTS AND IUDS, 2004-2011 ($ BILLIONS)
- Figure 21 U.S. MARKET FOR TDDS, 2004-2011 ($ BILLIONS)
- Figure 22 U.S. MARKET FOR TARGETED DELIVERY SYSTEMS 2004-2011 ($ MILLIONS)
- Figure 23 U.S. MARKET FOR TRANSMUCOSAL DELIVERY SYSTEMS, 2004-2011 ($ MILLIONS)
- Figure 24 ANNUAL NUMBER OF PATENTS, 2003-2006 (UNITS)
- Figure 25 ANNUAL NUMBER OF PATENTS, 2003-2005 (%)
- Figure 26 NUMBER OF DRUG DELIVERY PATENTS BY CATEGORY, 2003-2006 (UNITS)
- Figure 27 DRUG DELIVERY PATENTS BY CATEGORY, 2003-2006 (%)
- Figure 28 SHARES OF U.S. PATENTS BY ASSIGNEE, 2003-2006 (UNITS)
- Figure 29 SHARES OF U.S. PATENTS BY ASSIGNEE, 2003-2006 (%)
- Figure 30 U.S. MARKET FOR CARDIOVASCULAR DRUG DELIVERY SYSTEMS, 2004-2011 ($ BILLIONS)
- Figure 31 U.S. MARKET FOR ONCOLOGY DRUG DELIVERY SYSTEM, 2004-2011 ($ BILLIONS)
- Figure 32 U.S. MARKET FOR UROLOGY DRUG DELIVERY SYSTEMS, 2004-2011 ($ BILLIONS)
- Figure 33 U.S. MARKT FOR DIABETES DRUG DELIVERY SYSTEMS, 2004-2011 ($ BILLIONS)
- Figure 34 U.S. MARKET FOR RESPIRATORY DRUG DELIVERY SYSTEMS, 2004-2011 ($ BILLIONS)
- Figure 35 U.S. MARKET FOR ANTI-INFLAMMATORY AND ALLERGY DRUG DELIVERY SYSTEMS, 2004-2011 ($ BILLIONS)
- Figure 36 U.S. MARKET FOR ANTIBIOTIC DRUG DELIVERY SYSTEMS, 2004-2011 ($ BILLIONS)
- Figure 37 U.S. MARKET FOR ANTI-ANXIETY AND ANTI-DEPRESSANT DRUG DELIVERY SYSTEMS, 2004-2011 ($ BILLIONS)
- Figure 38 U.S. MARKET FOR HORMONES AND GYNECOLOGY DRUG DELIVERY SYSTEMS, 2004-2011 ($ BILLIONS)
- Figure 39 U.S. MARKET FOR OPHTHALMIC DRUG DELIVERY SYSTEMS, 2004-2011 ($ BILLIONS)
- Figure 40 U.S. MARKET FOR IMMUNE DISEASEDRUG DELIVERY SYSTEMS, 2004-2011 ($ BILLION)
- Figure 41 U.S. MARKET FOR OTHERS CATEGORY IN DRUG DELIVERY SYSTEMS, 2004-2011 ($ BILLIONS)
- Figure 42 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS, 2005 (%)
- Figure 43 GLOBAL MARKET FOR SUSTAINED RELEASE DOSAGE (ORAL, INJECTABLE, TOPICAL) DRUG DELIVERY SYSTEMS, 2004-2011 ($ BILLIONS)
- Figure 44 GLOBAL MARKET FOR IMPLANTS AND IUD DRUG DELIVERY SYSTEMS, 2004-2011 ($ BILLIONS)
- Figure 45 GLOBAL MARKET FORECAST FOR TRANSDERMAL DRUG DELIVERY SYSTEMS, THROUGH 2011 ($ BILLIONS)
- Figure 46 GLOBAL MARKET FOR TARGETED DRUG DELIVERY SYSTEMS, 2004-2011 ($ BILLIONS)
- Figure 47 GLOBAL MARKET FOR TRANSMUCOSAL DRUG DELIVERY SYSTEMS 2004-2011 ($ BILLION)
